Femme is a probiotic complex by SynBalance, specifically designed to support women’s intimate health.
Femme has been clinically tested to confirm the effectiveness in humans. The first clinical trial has investigated the ability of probiotic strains to colonize and persist in the vagina through oral intake. In a RDBPC trial 40 healthy women were enrolled and asked to take either Femme, 3B CFU/day or placebo for 14 days. PCR results related to the treatment and the follow-up periods, have demonstrated that Femme strains can reach the vagina from the gastrointestinal tract, colonize and persist (p<0,05). Femme has been further investigated to evaluate the reduction of relapses in women with BV: 75 women suffering from bacterial vaginosis were enrolled and treated with antibiotic for 5 days. Next, volunteers have been split into two groups: 50 women continued with probiotic intake (3B CFU per day) for 14 days after antibiotic treatment plus 7 days per month for the following 4 months, while the last 25 were monitored as control group without probiotic intake. Results demonstrated that the recurrence rate dropped at 16% in active group with respect to 40% of control group (p<0,01), in line with epidemiological data (40-60%). Additionally, the active group reported to perceive an improvement of the clinical markers associated to BV.
The last clinical trial performed aimed at investigating the role of probiotic ingredients in modulating the vaginal microbiota in menopausal women observing after just one month a higher abundance of Lactobacilli species as well as improvement of vaginal well-being. 

Scientific reference(s)

Reference: Mezzasalma, Valerio, et al. ""Orally administered multispecies probiotic formulations to prevent uro-genital infections: a randomized placebo-controlled pilot study."" Archives of gynecology and obstetrics 295.1 (2017): 163-172. Murina, Filippo, and Franco Vicariotto. ""Evaluation of an Orally Administered Multistrain Probiotic Supplement in Reducing Recurrences Rate of Bacterial Vaginosis: A Clinical and Microbiological Study."" Advances in Infectious Diseases 9.3 (2019): 151-161.
L. plantarum PBS067, L. rhamnosus LRH020 and B. lactis BL050 (composing Femme) have been selected as the most performing strains in the prevention and support of women’s urogenital infections. We have deeply investigated mechanisms of action in several in-vitro and ex-vivo models against a wide range of urogenital pathogens as G. vaginalis, C. albicans, E. coli, N. gonorrhoeae, T. vaginalis, confirming a strong antimicrobial spectrum. Presti, I., et al. ""Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect."" Applied microbiology and biotechnology 99.13 (2015): 5613-5626. Malfa, Patrizia, et al. ""Evaluation of Antimicrobial, Antiadhesive and Co-Aggregation Activity of a Multi-Strain Probiotic Composition against Different Urogenital Pathogens."" International Journal of Molecular Sciences 24.2 (2023): 1323.

Additional info

Therapeutical area(s)

Urogenital system · Women health


Gut permeability · Immune stimulation · Vaginal candidiasis



Dosage form



3 billion(s)
Scroll to Top
Browse companies by type
Brought to you by